well
import
prespecifi
subgroup
alic
e
like
therefor
enhanc
evid
base
support
import
common
area
clinic
practic
introduct
effect
manag
season
pandem
influenza
high
prioriti
intern
guidelin
mani
countri
recommend
antivir
treatment
older
peopl
individu
comorbid
increas
risk
complic
howev
antivir
often
prescrib
primari
care
europ
partli
clinic
cost
effect
insuffici
demonstr
nonindustri
fund
pragmat
studi
method
analysi
antivir
influenzalik
ill
rct
clinic
cost
effect
primari
care
european
multin
multicentr
openlabel
nonindustri
fund
pragmat
adaptiveplatform
randomis
control
trial
initi
trial
arm
best
usual
primari
care
best
usual
primari
care
plu
treatment
oseltamivir
day
aim
recruit
least
particip
year
present
influenzalik
ill
ili
symptom
durat
hour
primari
care
three
consecut
period
confirm
high
influenza
incid
particip
outcom
follow
day
diari
telephon
primari
object
determin
whether
ad
antivir
treatment
best
usual
primari
care
effect
reduc
time
return
usual
daili
activ
fever
headach
muscl
ach
reduc
minor
sever
less
secondari
object
includ
estim
costeffect
benefit
subgroup
accord
age
year
sever
symptom
present
low
medium
high
comorbid
yesno
durat
symptom
hour
hour
complic
hospit
admiss
pneumonia
use
addit
prescrib
medic
includ
antibiot
use
overthecount
medicin
selfmanag
ili
symptom
ethic
dissemin
research
ethic
committe
rec
approv
grant
nre
committe
south
central
oxford
b
clinic
trial
author
cta
approv
medicin
healthcar
product
regulatori
agenc
particip
countri
gain
nation
rec
cta
approv
requir
dissemin
result
peerreview
scientif
journal
confer
present
trial
registr
number
preresult
strength
limit
studi
antivir
influenzalik
ill
rct
clinic
cost
effect
primari
care
alic
e
first
publicli
fund
multicountri
pragmat
studi
determin
whether
antivir
routin
prescrib
influenzalik
ill
primari
care
prespecifi
characterist
age
symptom
durat
ill
sever
comorbid
influenc
outcom
platform
design
allow
studi
remain
relev
evolv
circumst
abil
add
treatment
arm
respons
adapt
allow
proport
particip
key
characterist
alloc
studi
arm
alter
cours
trial
accord
emerg
outcom
data
particip
inform
use
increas
chanc
receiv
intervent
effect
sinc
possibl
take
placebo
influenc
particip
expect
treatment
determin
effect
intervent
patient
behaviour
realworld
care
critic
estim
cost
effect
alic
e
design
openlabel
trial
open
design
carri
risk
bia
particip
selfreport
outcom
clear
explan
equipois
recruit
may
mitig
influenza
viru
highli
contagi
repres
common
caus
respiratori
infect
local
system
symptom
annual
influenza
epidem
account
consider
morbid
mortal
influenza
outbreak
potenti
becom
pandem
effect
control
manag
season
pandem
influenza
high
prioriti
nation
govern
routin
use
antivir
agent
rare
european
primari
care
gener
practition
gp
europ
gener
advis
patient
consult
influenzalik
ill
ili
take
paracetamol
nonsteroid
antiinflammatori
drug
either
requir
regular
interv
may
also
provid
advic
overthecount
otc
medicin
selfmanag
ili
symptom
exampl
maintain
fluid
bed
rest
take
time
work
school
broad
approach
current
consid
best
usual
care
empir
manag
ili
europ
current
suitabl
antivir
agent
avail
pragmat
evalu
antivir
influenzalik
ill
rct
clinic
cost
effect
primari
care
alic
e
oseltamivir
tamiflu
neuraminidas
inhibitor
ni
us
food
drug
administr
approv
oseltamivir
oseltamivir
classifi
essenti
medicin
mani
countri
stockpil
drug
ensur
readili
avail
treat
season
pandem
influenza
oseltamivir
could
therefor
use
manag
ili
assumpt
mani
case
ili
may
caus
influenza
probabl
higher
confirm
period
heighten
influenza
base
nation
report
ili
consult
laboratoryconfirm
influenza
case
oseltamivir
phosphat
oral
prodrug
undergo
hydrolysi
hepat
esteras
form
activ
oseltamivir
carboxyl
oseltamivir
carboxyl
act
select
inhibit
influenza
b
viral
neuraminidas
enzym
normal
promot
releas
viru
infect
cell
cleav
termin
sialic
acid
residu
surfac
host
cell
influenza
viru
envelop
facilit
viral
movement
within
respiratori
tract
block
activ
enzym
oseltamivir
prevent
new
viral
particl
releas
oseltamivir
might
also
modifi
immun
respons
influenza
infect
reduc
level
proinflammatori
cytokin
might
turn
modul
symptom
influenza
industrysponsor
trial
studi
efficaci
studi
clinic
studi
report
ni
often
oseltamivir
subject
mani
systemat
review
metaanalys
includ
individu
patient
metaanalys
two
recent
metaanalys
differ
method
primari
outcom
measur
use
includ
almost
set
trial
jefferson
et
al
found
oseltamivir
improv
mean
time
first
allevi
symptom
placebo
hour
dobson
et
al
found
oseltamivir
improv
median
time
allevi
symptom
placebo
hour
review
also
found
oseltamivir
reduc
risk
selfreport
nonverifi
pneumonia
clinic
diagnos
pneumonia
dobson
et
al
furthermor
indic
treatment
oseltamivir
might
reduc
risk
lower
respiratori
tract
infect
complic
hospitalis
patient
test
posit
influenza
howev
increas
nausea
vomit
found
associ
oseltamivir
use
even
possibl
reduct
symptom
durat
compar
placebo
valu
oseltamivir
treatment
previous
healthi
individu
nonsever
season
influenza
question
convers
circumst
individu
exampl
urgent
need
return
work
parent
carer
may
mean
reduct
functionlimit
symptom
day
may
consid
worthwhil
uk
academi
medic
scienc
recent
review
current
evid
advis
addit
pragmat
trial
primari
care
costeffect
analys
take
virul
sever
circul
strain
account
requir
inform
judgement
sinc
oseltamivir
gener
sale
excess
us
usa
stockpil
million
treatment
cost
us
uk
spent
stockpil
million
dose
countri
possess
enough
oseltamivir
million
peopl
downgrad
oseltamivir
list
essenti
medicin
core
drug
one
complimentarya
categori
drug
consid
less
costeffect
howev
never
largescal
intern
publicli
fund
pragmat
randomis
control
trial
rct
costeffect
primari
care
evid
base
either
support
support
routin
use
agent
primari
care
inadequ
rais
question
effect
found
previou
efficaci
studi
translat
meaning
benefit
everi
day
primari
care
specif
overal
cost
benefit
possibl
shorten
symptom
durat
perspect
individu
suffer
health
servic
societi
patient
consid
higher
risk
complic
influenza
exampl
due
age
durat
sever
symptom
relev
comorbid
benefit
antivir
treatment
primari
care
answer
question
reduc
import
clinic
uncertainti
primari
care
clinician
whether
prescrib
antivir
agent
ili
whether
prioritis
antivir
treatment
subgroup
primari
care
patient
alic
e
trial
deliv
work
packag
platform
european
prepared
emerg
epidem
prepar
www
prepareeurop
eu
consortium
grant
prepar
european
commiss
fund
network
rapid
effici
deliveri
harmonis
largescal
clinic
research
studi
infecti
diseas
alic
e
rct
investig
open
access
medicin
product
primari
care
determin
clinicaleffect
costeffect
ad
antivir
agent
best
usual
primari
care
patient
specif
characterist
suffer
ili
thu
enabl
clinician
better
individualis
prescrib
decis
primari
object
alic
e
therefor
determin
whether
ad
antivir
treatment
best
usual
primari
care
effect
reduc
time
taken
return
usual
daili
activ
patient
ili
secondari
object
determin
whether
antivir
treatment
costeffect
benefit
prespecifi
subgroup
particip
decreas
hospit
admiss
decreas
complic
relat
ili
especi
pneumonia
improv
healthrel
qualiti
life
decreas
repeat
attend
gp
health
servic
decreas
time
first
reduct
time
allevi
newworsen
ili
symptom
reduc
use
otc
prescrib
medic
includ
antibiot
affect
selfmanag
ili
symptom
protocol
alic
e
report
accord
standard
protocol
item
recommend
intervent
trial
spirit
guidelin
particip
provid
written
inform
consent
particip
studi
conduct
use
good
clinic
practic
guidelin
accord
principl
declar
helsinki
accord
relev
nation
guidelin
regul
act
independ
data
monitor
committe
review
efficaci
safeti
data
treatment
alloc
trial
steer
committe
tsc
provid
oversight
trial
manuscript
result
primari
outcom
publish
peerreview
journal
addit
manuscript
report
secondari
outcom
submit
public
peerreview
journal
relev
necess
research
question
studi
design
develop
patient
face
document
includ
consent
form
particip
inform
sheet
symptom
diari
followup
form
promot
materi
review
member
public
patient
public
involv
group
includ
mixtur
research
experienc
inexperienc
peopl
parent
elderli
member
public
part
tsc
repres
relev
patient
group
involv
continu
review
recruit
conduct
studi
tsc
meet
held
least
per
year
recruit
season
intervent
arm
alic
e
use
antivir
addit
best
usual
primari
care
burden
particip
assess
tsc
consid
minim
antivir
current
assess
alic
e
oseltamivir
licens
medic
market
authoris
global
context
alic
e
trial
standard
dose
oseltamivir
shown
well
toler
studi
use
standard
dose
oseltamivir
use
accord
market
authoris
grant
trial
particip
inform
trial
result
directli
howev
result
publish
prepar
consortium
websit
http
www
prepareeurop
eu
nuffield
depart
primari
care
websit
http
www
phc
ox
ac
uk
phctrial
access
freeli
network
particip
alic
e
european
multin
multicentr
openlabel
pragmat
adaptiveplatform
rct
twentyon
primari
care
clinic
research
network
european
countri
recruit
particip
figur
network
coordin
recruit
site
within
network
number
primari
care
research
network
alreadi
establish
collabor
genom
combat
resist
antibiot
communityacquir
lrti
europ
www
gracelrti
org
network
excel
sustain
translat
research
antimicrobi
resist
communityacquir
infect
europ
www
esf
org
trace
complement
prepar
alic
e
six
addit
primari
care
research
network
recruit
three
consecut
influenza
season
season
start
end
recruit
base
report
local
ili
incid
rise
fall
prespecifi
threshold
use
inform
suppli
european
centr
diseas
prevent
control
ecdc
local
region
sourc
network
aim
recruit
minimum
particip
recruit
site
gp
practic
primari
care
hour
ooh
servic
paediatr
centr
within
primari
care
potenti
particip
identifi
present
recruit
site
symptom
ili
telephon
appoint
advic
symptom
particip
must
meet
inclus
criteria
includ
symptom
onset
hour
less
none
exclus
criteria
tabl
definit
ili
use
alic
e
base
ecdc
definit
flexibl
maximis
recruit
children
elderli
elig
will
particip
particip
complet
rest
initi
trial
procedur
either
within
visit
second
appoint
recruit
recruit
site
home
local
implement
trial
builtin
flexibl
local
network
recruit
process
vari
exampl
medic
student
may
assist
recruit
task
certain
practic
wherea
other
incorpor
triag
system
addit
trialspecif
clinic
andor
research
support
staff
recruit
process
open
access
randomis
blind
obtain
inform
written
consent
particip
randomis
point
care
use
remot
onlin
electron
data
captur
system
research
onlin
emerg
randomis
procedur
avail
webbas
facil
temporarili
unavail
randomis
initi
ratio
two
arm
stratif
subgroup
accord
ecdc
definit
higher
risk
complic
influenza
name
age
year
sever
symptom
low
medium
high
relev
comorbid
yesno
durat
symptom
heart
diseasediabeteschron
respiratori
condit
eg
asthma
chronic
obstruct
pulmonari
diseas
hepat
hematolog
neurolog
neurodevelopment
conditionstrok
transient
ischaem
open
access
sinc
onset
hour
hour
proport
randomis
studi
arm
may
alter
cours
trial
follow
prespecifi
bayesian
respons
adapt
approach
alic
e
open
trial
particip
recruit
clinician
studi
personnel
awar
particip
alloc
open
pragmat
trial
chosen
design
better
determin
effect
routin
care
patient
much
less
tightli
supervis
estim
effect
placebocontrol
efficaci
trial
may
translat
similar
effect
size
intervent
taken
routin
clinic
care
knowledg
medic
one
take
influenc
helpseek
behaviour
decis
reconsult
may
substanti
affect
costeffect
addit
efficaci
estim
alreadi
repeatedli
determin
efficaci
trial
tightli
control
inclus
criteria
children
elderli
peopl
comorbid
underrepres
clinician
prescrib
placebo
routin
care
credibl
compar
current
best
practic
therefor
unblind
code
break
requir
event
relev
emerg
howev
trial
team
blind
treatment
alloc
aggreg
level
recruit
promot
equipois
particip
attackovernight
hospit
admiss
last
year
two
arm
care
cover
trialspecif
train
arm
trial
support
routin
practic
previou
open
pragmat
trial
abl
minimis
placebo
effect
use
approach
intervent
particip
randomis
best
usual
primari
care
plu
oseltamivir
arm
given
dose
mg
oseltamivir
two
time
per
day
day
oral
rout
capsul
year
year
year
dose
two
time
per
day
day
suspens
administ
oral
accord
weight
mg
mg
mg
mg
children
weigh
kg
abl
swallow
capsul
may
receiv
treatment
adult
dosag
mg
capsul
two
time
per
day
day
altern
dose
oseltamivir
suspens
rout
administr
dosag
treatment
period
follow
manufactur
summari
product
characterist
weight
measur
children
year
recruit
visit
medic
dose
particip
ask
weight
baselin
assess
measur
case
uncertainti
daili
symptom
diari
subsequ
day
telephon
call
use
monitor
intervent
complianc
togeth
telephon
call
day
also
ascertain
minim
data
set
outcom
symptom
durat
hour
less
abl
will
compli
trial
requir
particip
legal
guardian
child
will
abl
give
inform
consent
agre
take
antivir
agent
apart
studi
antivir
agent
accord
patient
randomis
chronic
renal
failur
exampl
known
estim
creatinin
glomerular
filtrat
rate
mlmin
knownrecord
particip
clinic
record
condit
treatment
associ
signific
impair
immun
eg
longterm
oral
steroid
chemotherapi
immun
disord
knownrecord
particip
clinic
record
opinion
respons
clinician
prescrib
immedi
antivir
treatment
allerg
oseltamivir
trial
medic
schedul
elect
surgeri
procedur
requir
gener
anaesthesia
subsequ
week
particip
life
expect
estim
clinician
less
month
patient
sever
hepat
impair
respons
clinician
consid
urgent
hospit
admiss
requir
signific
diseas
disord
opinion
respons
clinician
may
either
put
particip
risk
particip
trial
may
influenc
result
trial
may
affect
particip
abil
particip
trial
involv
includ
complet
followup
procedur
anoth
clinic
trial
investig
medicin
product
last
day
previou
antivir
influenzalik
ill
rct
clinic
cost
effect
primari
care
trial
particip
patient
unabl
randomis
within
hour
onset
symptom
requir
live
viral
vaccin
next
day
option
accord
specif
countri
legisl
pregnant
lactat
breastfeed
women
ili
influenzalik
ill
primari
outcom
patient
report
time
return
usual
daili
activ
fever
headach
muscl
ach
symptom
rate
problem
nonverb
children
clingi
replac
headach
muscl
ach
unansw
secondari
outcom
includ
collect
day
costeffect
measur
healthcar
resourc
use
healthrel
qualiti
life
effect
subgroup
particip
base
age
band
initi
ill
sever
relev
comorbid
durat
symptom
laboratoryconfirm
influenza
ab
posit
hospit
admiss
overnight
stay
attend
gp
practic
hospit
emerg
care
primari
care
ooh
servic
paediatr
centr
complic
relat
ili
andor
potenti
relev
complic
pneumonia
time
first
reduct
time
allevi
new
worsen
ili
symptom
use
prescript
medic
includ
antibiot
use
otc
medic
particip
report
selfmanag
usual
daili
activ
tabl
outlin
alic
e
schedul
procedur
accord
spirit
guidelin
baselin
assess
day
obtain
written
inform
consent
recruit
complet
baselin
case
report
form
crf
includ
requir
inform
randomis
age
relev
comorbid
durat
symptom
clinician
rate
sever
ili
mild
moder
sever
addit
crf
ascertain
particip
parent
sever
grade
fever
run
congest
nose
sore
throat
headach
cough
short
breath
muscl
ach
pain
sweatschil
diarrhoea
nausea
andor
vomit
abdomin
pain
low
energytir
sleep
well
dizzi
feel
gener
unwel
gradingno
minor
moder
major
problem
inform
usual
care
advic
given
particip
type
healthcar
coverag
eg
public
privat
mix
symptom
question
supplement
childspecif
question
canadian
acut
respiratori
ill
influenza
scale
complet
children
year
addit
clinic
examin
find
record
includ
temperatur
way
measur
oral
ear
axilla
use
antipyret
last
hour
puls
rate
weight
year
case
uncertainti
height
smoke
statu
gender
whether
influenza
vaccin
within
month
pneumococc
vaccin
within
year
recruit
provid
antivir
medic
accord
particip
group
alloc
standardis
instruct
take
medic
recruit
also
take
oropharyng
nasal
swab
copan
year
nasopharyng
swab
copan
year
swab
place
ml
univers
transport
media
transport
local
laboratori
storag
final
instruct
particip
complet
symptom
diari
give
inform
telephon
followup
assess
requir
particip
attend
facetofac
followup
visit
part
studi
particip
subsequ
measur
ascertain
selfcomplet
diarybas
questionnair
telephon
call
local
trial
team
particip
legal
guardian
carer
ask
complet
symptom
diari
day
baselin
day
randomis
follow
data
point
collect
expect
treatment
open
access
benefit
ethnic
employ
statu
cohabit
pregnanc
stage
current
longterm
medic
follow
data
point
collect
daili
diari
sever
select
ili
symptom
qualiti
life
euroqol
visual
analogu
scale
va
return
usual
daili
activ
prescript
medic
use
includ
antibiot
use
otc
medic
remedi
adher
trial
medic
potenti
side
effect
day
follow
data
point
collect
weekli
qualiti
life
use
index
respond
year
respond
year
effect
particip
symptom
usual
daili
activ
healthcar
resourc
use
outofpocket
expenditur
ili
state
peopl
household
particip
legal
guardian
telephon
day
day
day
defin
day
recruit
studi
offer
support
symptom
diari
complet
check
urgent
issu
also
telephon
day
day
ask
day
return
usual
daili
activ
fever
headach
muscl
ach
symptom
reduc
minor
sever
less
ensur
primari
endpoint
collect
particip
ascertain
seriou
advers
event
sae
preced
week
particip
receiv
final
telephon
call
day
complet
verbal
va
answer
remain
question
symptom
resolut
need
trial
particip
consent
process
part
process
evalu
see
trial
team
ask
whether
particip
recurr
symptom
time
whether
admit
hospit
result
symptom
particip
visit
hospit
complic
possibl
relat
ili
chest
xray
primari
care
clinic
record
examin
trial
team
confirm
relev
diagnos
complic
includ
pneumonia
swab
receiv
local
laboratori
sampl
frozen
store
accept
deep
freezer
influenza
season
sampl
transport
laboratori
medic
microbiolog
univers
antwerp
belgium
analysi
particip
swab
analys
use
multiplex
rtpcr
detect
pathogen
gene
taqman
technolog
identifi
whether
particip
infect
influenza
b
respiratori
virus
ii
bacteria
iii
ii
rhinoviru
coronaviru
parainfluenza
interview
qualit
assess
part
day
telephon
call
particip
legal
guardian
carer
question
ask
motiv
particip
alic
e
studi
influenc
decis
question
relat
research
particip
pandem
particip
clinician
ask
complet
brief
questionnair
subsampl
ask
perspect
trial
process
view
influenza
manag
primari
care
particip
pandem
research
safeti
discontinu
withdraw
particip
trial
treatment
oseltamivir
welldocu
safeti
profil
commonli
use
medic
primari
care
set
result
nonsa
record
studi
sae
occur
day
particip
enrol
trial
record
left
investig
clinic
judgement
decid
whether
symptom
side
effect
suffici
sever
requir
particip
remov
treatment
particip
withdrawn
due
advers
event
ae
investig
arrang
followup
visit
telephon
call
ae
resolv
stabilis
end
trial
particip
whichev
later
particip
withdrawn
due
ae
followup
data
continu
collect
inform
includ
purpos
intent
treat
itt
analysi
particip
right
withdraw
studi
time
without
prejudic
current
futur
healthcar
respons
adaptiveplatform
trial
design
adapt
platform
trial
enabl
multipl
intervent
indic
test
simultan
within
master
protocol
often
includ
capac
add
drop
studi
arm
studi
progress
platform
trial
provid
effect
framework
studi
patient
heterogen
outcom
goal
determin
best
treatment
variou
subgroup
patient
addit
platform
trial
design
incorpor
respons
adapt
randomis
order
randomis
particip
best
perform
intervent
cours
trial
increas
statist
power
effici
trial
well
lead
better
patient
outcom
cours
studi
chose
adapt
platform
trial
design
provid
flexibl
evalu
addit
intervent
trial
intervent
emerg
suitabl
pragmat
evalu
primari
care
addit
design
provid
abil
prospect
identifi
particular
subgroup
interest
may
receiv
benefit
antivir
agent
oppos
estim
singl
overal
effect
done
incorpor
bayesian
model
approach
combin
respons
adapt
randomis
base
prespecifi
particip
characterist
multipl
interim
analys
open
access
recruit
plan
everi
patient
andor
influenza
season
alic
e
particip
initi
randomis
ratio
two
arm
stratif
subgroup
random
block
arm
maintain
least
probabl
randomis
within
subgroup
throughout
cours
trial
arm
superior
assess
subgroup
may
declar
superior
subgroup
within
other
interim
analysi
arm
meet
superior
criterion
one
treatment
randomis
probabl
may
modifi
subgroup
minimum
particip
alloc
inferior
arm
remain
alloc
superior
arm
maximum
two
arm
event
stratif
block
longer
occur
within
subgroup
ensur
major
particip
receiv
bestknown
therapi
yet
trial
design
still
allow
assess
season
variat
popul
chang
studi
popul
time
addit
still
abl
collect
data
cost
healthrel
behaviour
includ
healthcar
seek
associ
poorli
perform
arm
new
compar
arm
may
enter
trial
determin
tsc
elig
therapi
includ
newli
approv
treatment
ili
therapi
recommend
public
health
agenc
influenza
pandem
arm
ad
trial
prespecifi
algorithm
determin
randomis
ratio
activ
respons
adapt
randomis
within
subgroup
respect
treatment
arm
oper
characterist
trial
updat
via
simul
howev
gener
structur
trial
chang
respons
adapt
randomis
may
activ
subgroup
without
satisfi
superior
criterion
number
intervent
greater
two
justif
sampl
size
sampl
size
calcul
plan
design
avail
use
tradit
formula
instead
simul
must
use
estim
oper
characterist
adapt
algorithm
includ
estim
mani
particip
particular
characterist
requir
order
detect
differ
treatment
simul
prespecifi
algorithm
appli
randomis
particip
particular
prespecifi
characterist
depend
number
arm
collect
outcom
data
addit
algorithm
determin
arm
drop
futil
intervent
declar
superior
process
ad
new
intervent
platform
trial
particip
recruit
three
consecut
winter
rang
chosen
ensur
suffici
power
comparison
overal
popul
well
within
prespecifi
subgroup
given
natur
studi
adapt
design
desir
ensur
suffici
power
multipl
hypothes
across
sever
subgroup
number
particip
need
recruit
complex
multidimension
calcul
henc
numer
simul
conduct
calcul
power
variou
plausibl
scenario
maximum
target
particip
chosen
simul
gave
power
mani
subgroup
analys
benefit
term
symptom
relief
oseltamivir
particip
provid
power
compar
primari
endpoint
overal
studi
popul
least
benefit
oseltamivir
particip
confirm
influenza
number
also
provid
power
subgroup
benefit
oseltamivir
particip
confirm
influenza
base
simul
assumpt
patient
confirm
influenza
patient
ili
origin
anoth
viral
infect
primari
analysi
itt
includ
randomis
particip
treatment
arm
assign
regardless
treatment
taken
secondari
analys
includ
subset
itt
popul
confirm
influenza
least
one
interim
analysi
accrual
data
collect
season
complet
recruit
open
subsequ
influenza
season
accrual
rapid
larg
number
patient
enrol
exampl
case
influenza
pandem
one
interim
analysi
may
conduct
influenza
season
occur
approxim
addit
patient
enrol
adapt
randomis
probabl
may
updat
arm
assess
superior
interim
analysi
composit
primari
endpoint
return
usual
activ
resolut
fever
muscl
ach
headach
minor
problem
less
model
accord
bayesian
piecewis
exponenti
model
surviv
time
model
allow
baselin
hazard
vari
across
followup
hazard
reach
primari
endpoint
model
four
time
day
day
day
day
particip
reach
primari
endpoint
day
includ
particip
die
consid
censor
day
particip
withdraw
lost
followup
evalu
primari
endpoint
reason
consid
censor
last
contact
date
day
whichev
earlier
costeffect
analysi
compar
direct
medic
cost
health
outcom
term
number
day
ili
limit
usual
activ
term
qualiti
adjust
life
year
gain
differ
arm
analysi
use
data
trial
resourc
use
va
score
relev
data
countri
trial
set
eg
unit
cost
type
healthcar
provid
within
countri
potenti
differ
repeat
measur
va
arm
investig
perparticip
basi
use
mixedeffect
model
valuat
qualiti
life
use
standardis
instrument
measur
gener
health
statu
done
accord
guidelin
euroqol
group
use
crosswalk
index
valu
calcul
uncertainti
explor
use
bootstrap
repres
cloud
increment
costeffect
ratio
costeffect
plane
well
costeffect
accept
curv
subgroup
analys
perform
acknowledg
heterogen
within
arm
trial
eg
age
sever
countri
valu
perfect
inform
analysi
may
also
perform
identifi
sourc
uncertainti
reduc
addit
research
effici
improv
decis
make
alic
e
trial
first
largescal
intern
nonindustrysponsor
pragmat
randomis
trial
cost
effect
ad
oseltamivir
best
usual
primari
care
peopl
suffer
ili
alic
e
open
trial
order
approxim
effect
condit
close
usual
care
order
determin
realworld
estim
cost
effect
open
trial
criticis
treatment
appear
benefici
may
clear
effect
result
biolog
mechan
placebo
effect
consid
possibl
outcom
alic
e
benefit
found
antivir
arm
despit
compar
usual
care
arm
enhanc
possibl
effect
placebo
prescrib
antivir
agent
recommend
hand
benefit
antivir
agent
identifi
pragmat
trial
given
drug
efficaci
alreadi
demonstr
mani
placebocontrol
trial
drug
mechan
action
known
specif
condit
studi
would
obtus
suggest
benefit
alic
e
may
identifi
deriv
placebo
effect
antivir
effect
influenza
lack
costeffect
analys
alongsid
clinic
trial
given
children
older
peopl
peopl
comorbid
underrepres
studi
done
highlight
decis
downgrad
statu
oseltamivir
despit
lack
trial
evid
model
list
essenti
medicin
state
use
oseltamivir
restrict
sever
ill
due
confirm
suspect
influenza
viru
infect
critic
ill
hospitalis
patient
anoth
report
quot
state
unless
new
inform
support
use
season
pandem
outbreak
provid
next
expert
committe
might
consid
oseltamivir
delet
current
uk
us
guidelin
recommend
treatment
defin
subgroup
frail
patient
patient
increas
risk
complic
sinc
evid
base
recommend
incomplet
withhold
treatment
patient
may
possibl
deni
benefit
includ
best
usual
primari
care
arm
studi
determin
ad
benefit
antivir
agent
current
practic
season
potenti
pandem
influenza
inform
great
import
deliveri
primari
care
ili
well
enhanc
evid
base
around
advoc
selfcar
mani
countri
patient
ili
symptom
advis
consult
selfmanag
patient
addit
risk
factor
seldom
routin
treat
antivir
agent
larg
absenc
evid
costeffect
overal
subgroup
interest
virul
spread
type
circul
influenza
strain
vari
season
season
alic
e
aim
recruit
three
winterinfluenza
season
countri
therebi
obtain
wide
applic
data
allow
us
determin
whether
benefit
otherwis
antivir
agent
influenc
season
furthermor
aim
includ
wide
agerang
particip
mani
differ
set
well
comorbid
addit
event
influenza
pandem
addit
intervent
arm
includ
decis
could
made
increas
maximum
sampl
size
adapt
design
offer
sever
advantag
tradit
studi
design
recruit
particular
arm
stop
predetermin
level
certainti
effect
noneffect
treatment
arm
reach
predefin
estim
precis
adapt
randomis
could
increas
chanc
particip
alloc
arm
inform
use
intervent
effect
lead
better
patient
care
better
patient
outcom
trial
progress
second
platform
design
allow
new
intervent
arm
ad
trial
benefit
comparison
exist
treatment
arm
head
head
way
flexibl
extend
potenti
pandem
situat
addit
altern
intervent
may
ad
accord
government
public
health
recommend
way
studi
remain
current
relev
clinic
practic
evolv
circumst
throughout
alic
e
novel
mani
way
provid
critic
inform
clinic
costeffect
ad
oseltamivir
best
current
ili
manag
condit
approxim
usual
care
overal
